Tjoapack to Invest in Automated Injectables Packaging Capabilities

Article

Tjoapack is investing in fully automated lines, including a PFS line with an initial capacity of 7 million syringes per year and a vial line with an eventual capacity of more than 12 million vials per year.

Tjoapack, a contract packaging organization, announced on Sept. 10, 2020 that it is investing in automated injectables packaging capabilities to meet customer demands for prefilled syringes (PFS) and vials.

A new, fully automated PFS line features an initial capacity of 7 million syringes per year and has the ability to assemble, automate insertion of plunger rods and back-stops, carry out inline labelling, and complete coding and vision control, a company press release said. It will be fully operational by the fourth quarter of 2021. A fully automated vial line will begin operations in the first quarter of 2021 and will increase its capacity to over 12 million vials per year.

“As new therapies emerge to address unmet patient needs for chronic ailments the demand for contract packaging organization[s] that can handle syringes and vials will continue to rise,” said Dexter Tjoa, CEO, Tjoapack, in the press release. “Technological advancements, improving patient compliance, beneficial reimbursement policies, and the rise of biologics in the pharmaceutical market will also further propel the needs for service providers who can meet these requirements.”

Source: Tjoapack

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content